Life Sciences Business Evolution Series: Funding Growth and the Future of Life Sciences

Life sciences companies intend to leverage new and existing sources of growth including through M&A, carve-outs, divestitures, partnerships, licensing and collaboration agreements as well as avenues tied to corporate PPAs and green financing. Find out about these trajectories as well as continued VC investment and increasing appetite from private equity sponsors in pre-revenue stages.
Read More

Navigating the ever-changing market reality requires responding to growing competition whilst managing cost pressures all while trying to achieve sustainable growth. Get well-rounded advice across 46 jurisdictions from a life sciences transactions team with a keen view of the transactional landscape, industry trends and regulatory outlook.

Explore more below.

Collaborations and Licensing

expand accordion
  • Complex multinational collaborations
  • Joint ventures
  • Commercialization agreements
  • Co-promotion agreements
  • Research and development agreements
  • Evaluation and option agreements

M&A

expand accordion
  • Product acquisitions and divestitures
  • Company sales and acquisitions
  • Business unit spinoffs
  • Post-acquisition integration

Financings

expand accordion
  • Equity financing
  • Royalty monetization
  • Development funding agreements

Operational Agreements

expand accordion
  • Manufacturing and supply agreements
  • Distribution agreements
  • Services agreements
  • University and other nonprofit agreements